AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Trimmed by Bleakley Financial Group LLC

Bleakley Financial Group LLC decreased its position in AstraZeneca PLC (NASDAQ:AZN) by 7.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,775 shares of the company’s stock after selling 5,200 shares during the quarter. Bleakley Financial Group LLC’s holdings in AstraZeneca were worth $3,982,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AZN. Stratos Wealth Advisors LLC boosted its stake in AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after acquiring an additional 133 shares during the period. Crumly & Associates Inc. lifted its holdings in shares of AstraZeneca by 2.2% in the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after purchasing an additional 143 shares during the last quarter. Diversify Wealth Management LLC boosted its position in AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after purchasing an additional 153 shares during the period. Veery Capital LLC grew its stake in AstraZeneca by 4.7% during the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock worth $230,000 after buying an additional 157 shares during the last quarter. Finally, Harbour Investments Inc. increased its position in AstraZeneca by 1.9% in the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after buying an additional 160 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AZN stock opened at $72.36 on Friday. The company has a market capitalization of $224.39 billion, a P/E ratio of 34.62, a PEG ratio of 1.18 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a 50-day simple moving average of $67.27 and a 200 day simple moving average of $73.70. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. Sell-side analysts predict that AstraZeneca PLC will post 4.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca currently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.